EC approval for post-steroid graft-versus-host treatment
Jakavi treats a potentially life-threatening condition which often effects transplant patients
Read More
Tag: GvHD
Novartis’ Jakavi bests current therapy for GvHD
REACH2 is the first Phase III study in steroid-refractory acute graft-versus-host-disease (GvHD) to have met its primary endpoint
Read More
FDA green lights first treatment for chronic GvHD
The US Food and Drug Administration has expanded the scope of Johnson & Johnson/AbbVie’s Imbruvica to include the treatment of adult patients with chronic graft versus host disease (cGVHD) after failure of one or more treatments, marking the first therapy specifically approved for the condition in the US.
Read More
Kymab’s antibody shows early promise in GvHD prophylaxis
UK group Kymab has unveiled what it says are “remarkable” early stage results for its new antibody therapy KY1005 in animal models of acute graft-versus-host-disease (GvHD).
Read More
Fourth breakthrough designation for Janssen’s Imbruvica
Janssen’s Imbruvica has picked up a fourth breakthrough designation as well as Orphan status from US regulators as a treatment for chronic graft-versus-host-disease (cGVHD).
Read More
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
- Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
- Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
- Title21 Health Solutions joins the Blood and Cells Advocacy Roster
- NADMED launches $30,000 metabolomics research award
